OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 464
- Registration Number
- NCT04092686
- Locations
- 🇺🇸
Arch Clinical Trials, LLC, Saint Louis, Missouri, United States
🇧🇬Mental Health Centre, Prof. Dr. Ivan Temkov, Burgas EOOD, Department for Treatment of Emergency Psychiatric Conditions, Burgas, Bulgaria
🇧🇬State Psychiatric Hospital Sv. Ivan rilski-Department General Psychiatry for Adults "closed" Type -Men, Department General Psychiatry for Adults, "Closed" Type - Women, Novi Iskar, Bulgaria
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2023-01-13
- Target Recruit Count
- 13
- Registration Number
- NCT04081363
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 463
- Registration Number
- NCT04072354
- Locations
- 🇺🇦
Dr. Vladyslav Demchenko, Kyiv, Ukraine
🇺🇸Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸Advanced Discovery Research LLC, Atlanta, Georgia, United States
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 266
- Registration Number
- NCT04030143
- Locations
- 🇺🇸
NRC Research Institute, Orange, California, United States
🇺🇸California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Woodland International Research Group, Rogers, Arkansas, United States
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-05-24
- Target Recruit Count
- 136
- Registration Number
- NCT03896945
- Locations
- 🇺🇸
Clinical Research Site# 840-083, Lafayette, California, United States
🇺🇸Clinical Research Site# 840-094, Doral, Florida, United States
🇺🇸Clinical Research Site #840-028, Berlin, New Jersey, United States
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 277
- Registration Number
- NCT03892889
- Locations
- 🇺🇸
CMB Clinical Trials, Colton, California, United States
🇺🇸Excell Research, Inc, Oceanside, California, United States
🇺🇸Precise Research Centers, Flowood, Mississippi, United States
Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 58
- Registration Number
- NCT03872596
- Locations
- 🇺🇸
Collaborative Neurosciences Network, LLC, Long Beach, California, United States
A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 72
- Registration Number
- NCT03854409
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸Community Clinical Research, Austin, Texas, United States
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-06-15
- Target Recruit Count
- 3
- Registration Number
- NCT03850509
- Locations
- 🇺🇸
United States, California, San Carlos, California, United States
🇺🇸United States, South Carolina, Rock Hill, South Carolina, United States
🇺🇸United States, Georgia, Doraville, Georgia, United States
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 122
- Registration Number
- NCT03678688
- Locations
- 🇿🇦
Satellite Site: Task at Brooklyn Chest Hospital, Cape Town, South Africa
🇿🇦University of Cape Town (Pty) Ltd., Cape Town, Mowbray, South Africa
🇿🇦TASK Clinical Research Centre, Cape Town, South Africa